Overall, the above results suggest that MM patients in the high-ARRS group may be resistant to protein kinase inhibitors, DNA damaging drugs, and PI3K/Akt/mTOR signaling pathway targeted drugs compared to low-ARRS MM. This evidence concerns the gene WEE1 and Miyoshi myopathy.